Literature DB >> 19399400

ANG II-AT1 receptor pathway is involved in the anti-fibrotic effect of beta-elemene.

Rui Zhu1, Ling Yang, Lin Shen, Jin Ye, Jianguo Liu, Shenjun Hu.   

Abstract

To investigate the effects of beta-elemene on the ANG II-AT1 receptor pathway in rats with liver fibrosis, a model of hepatic fibrosis was induced by hypodermical injection of carbon tetrachloride (CCl4) into Wistar male rats. beta-elemene was intraperitonealy administered into the rats for 8 weeks (0.1 mL/100 g body weight per day). Masson staining was used to observe the liver fibrosis of rats and liver functions were measured by enzymatic kinetic analysis. The content of hydroxyproline in liver tissues was detected by specimen alkaline hydrolysis. The level of plasma ANG in blood II plasma was detected by radioimmunoassay. The expression of AT1R in rat liver were measured using reverse transcriptional-polymerase chain reaction and immunohistochemistry respectively. The results showed that beta-elemene could reduce the collagen disposition in liver and inhibit the progression of liver fibrosis. In addition, the levels of plasma ANG II and the expression of hepatic AT1R in rats with liver fibrosis were also suppressed by beta-elemene. It is concluded that the ANG II-AT1 receptor pathway plays an important role in the development of hepatic fibrosis and beta-elemene could down-regulate the levels of plasma ANG II and the expression of hepatic AT1R in rats with liver fibrosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19399400     DOI: 10.1007/s11596-009-0208-z

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  22 in total

1.  Angiotensin II and Aldosterone stimulating NF-kappaB and AP-1 activation in hepatic fibrosis of rat.

Authors:  Xu Li; Ying Meng; Pingsheng Wu; Zhenshu Zhang; Xishan Yang
Journal:  Regul Pept       Date:  2006-09-12

2.  Host genetic factors influence disease progression in chronic hepatitis C.

Authors:  E E Powell; C J Edwards-Smith; J L Hay; A D Clouston; D H Crawford; C Shorthouse; D M Purdie; J R Jonsson
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

3.  Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis.

Authors:  G Paizis; R E Gilbert; M E Cooper; P Murthi; J M Schembri; L L Wu; J R Rumble; D J Kelly; C Tikellis; A Cox; R A Smallwood; P W Angus
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

Review 4.  Angiotensin II receptors and angiotensin II receptor antagonists.

Authors:  P B Timmermans; P C Wong; A T Chiu; W F Herblin; P Benfield; D J Carini; R J Lee; R R Wexler; J A Saye; R D Smith
Journal:  Pharmacol Rev       Date:  1993-06       Impact factor: 25.468

5.  The regulatory role of AT 1 receptor on activated HSCs in hepatic fibrogenesis:effects of RAS inhibitors on hepatic fibrosis induced by CCl(4).

Authors:  Hong-Shan Wei; Han-Ming Lu; Ding-Guo Li; Yu-Tao Zhan; Zhi-Rong Wang; Xin Huang; Ji-Lin Cheng; Qin-Fang Xu
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

6.  [The effect of angiotensin II type 1 receptor blocker valsartan in preventing hepatic fibrosis induced by dimethylnitrosamine in rats].

Authors:  Feng-jun Shen; Yue-ke Zhu; Ji-dong Jia; Hong Ma; Bao-en Wang
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2004-10

Review 7.  WITHDRAWN: Elemene for the treatment of lung cancer.

Authors:  Rui Dong; Xiao Y Chen; Taixiang Wu; Guan J Liu
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

8.  Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats.

Authors:  Yao Hong Wei; Li Jun; Chen Ji Qiang
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

9.  Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension.

Authors:  Vincent Croquet; Frédéric Moal; Nary Veal; Jianhua Wang; Frédéric Oberti; Jérôme Roux; Eric Vuillemin; Yves Gallois; Olivier Douay; Daniel Chappard; Paul Calès
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

10.  Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats.

Authors:  Masaru Ueki; Masahiko Koda; Satoru Yamamoto; Yoshiko Matsunaga; Yoshikazu Murawaki
Journal:  J Gastroenterol       Date:  2006-11-09       Impact factor: 6.772

View more
  6 in total

1.  Downregulation effects of beta-elemene on the levels of plasma endotoxin, serum TNF-alpha, and hepatic CD14 expression in rats with liver fibrosis.

Authors:  Jianguo Liu; Zhe Zhang; Jiechang Gao; Jiwen Xie; Lin Yang; Shenjun Hu
Journal:  Front Med       Date:  2011-03-17       Impact factor: 4.592

2.  Effects of Yinchenhao decoction on self-regulation of renin-angiotensin system by targeting angiotensin converting enzyme 2 in bile duct-ligated rat liver.

Authors:  Lin Wu; Pi-Qi Zhou; Ji-Wen Xie; Rui Zhu; Sun-Chang Zhou; Geng Wang; Zhong-Xu Wu; Sha Hao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-07-31

3.  The influence of astragalus polysaccharide and β-elemene on LX-2 cell growth, apoptosis and activation.

Authors:  Jin Zheng; Li-tian Ma; Qin-you Ren; Lu Li; Yi Zhang; Heng-jun Shi; Yi Liu; Cheng-hua Li; Yong-qi Dou; Shao-dan Li; Hui Zhang; Ming-hui Yang
Journal:  BMC Gastroenterol       Date:  2014-12-31       Impact factor: 3.067

Review 4.  LOX-1 and angiotensin receptors, and their interplay.

Authors:  Xianwei Wang; M Ian Phillips; Jawahar L Mehta
Journal:  Cardiovasc Drugs Ther       Date:  2011-10       Impact factor: 3.727

5.  β-Elemene Improves Morphine Tolerance in Bone Cancer Pain via N-Methyl-D-Aspartate Receptor 2B Subunit-Mediated μ-Opioid Receptor.

Authors:  Qinfei Zhou; Liyan Gong; Guanai Bao; Qunfang Ding; Jingjing Ji
Journal:  Comput Math Methods Med       Date:  2022-09-17       Impact factor: 2.809

Review 6.  A Review on Ethnopharmacological Applications, Pharmacological Activities, and Bioactive Compounds of Mangifera indica (Mango).

Authors:  Meran Keshawa Ediriweera; Kamani Hemamala Tennekoon; Sameera Ranganath Samarakoon
Journal:  Evid Based Complement Alternat Med       Date:  2017-12-31       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.